A group of international experts prepared two lists of drugs with their serum/plasma and urine concentrations, which should be used when evaluating the performance of a new laboratory method. The two lists were veri®ed by running in vitro interference studies in three European laboratories on Hitachi instruments. The study identi®ed the following new interferants: acid phosphatase in serum by ibuprofen and theophylline; non-prostatic acid phosphatase in serum by cefoxitin and doxycycline; creatine kinase MB in serum by doxycycline; total bilirubin in serum (Jendrassik±Grof method) by rifampicin and intralipid; total bilirubin in serum (DPD method) by intralipid; creatinine in serum (Jaffe method) by cefoxitin; fructosamine in serum by levodopa and methyldopa; uric acid in serum by levodopa, methyldopa and tetracycline; carbamazepine in serum by doxycycline, levodopa, methyldopa and metronidazole; digitoxin in serum by rifampcin; phenytoin in serum by doxycycline, ibuprofen, metronidazole and theophylline; theophylline in serum by acetaminophen, cefoxitin, doxycycline, levodopa, phenylbutazone and rifampicin; tobramycin in serum by cefoxitin, doxycycline, levodopa, rifampicin and phenylbutazone; valproic acid in serum by phenylbutazone; C3 in serum by intralipid; C4 in serum by doxycycline; rheumatoid factor in serum by ibuprofen and metronidazole; pancreatic amylase and total amylase in urine by acetylcysteine, ascorbic acid, cefoxitin, gentamicin, levodopa, methyldopa and o¯oxacin; magnesium in urine by acetylcysteine, gentamicin and methyldopa; b 2 -microglobulin in urine by ascorbic acid; total protein in urine by ascorbic acid, Ca-dobesilate and phenylbutazone.
INTRODUCTION
Drug interference studies are a necessary and integral part of method and instrument evaluation. Many hundreds of drugs are in clinical use; their blood and urine concentrations vary according to their clinical use and to pathological and physiological conditions. This presents a formidable problem to the diagnostic industry if it is to provide a systematic and clinically useful list of those drugs that interfere with laboratory tests. In 1978 an expert group was convened within the European Community to study drug interferences and establish recommendations. 1 In 1984 the French Society of Clinical Chemistry and the International Federation of Clinical Chemistry also addressed this issue and published, in French and in English, recommendations for the evaluation of drug interferences. 2, 3 The National Committee for Laboratory Standards published proposed guidelines for interference testing in 1986. 4 In 1995, under the chairmanship of J Breuer (Marienhospital, Gelsenkirchen, Germany) and with the support of Roche Diagnostics, a group of 18 international experts was formed to provide advice to the diagnostic industry and to others evaluating new methods and instruments. The group was charged with preparing a list of drugs with their serum/plasma and urine concentrations, which should be used when evaluating the performance of new clinical laboratory methods. The preliminary recommendations of the group were published in 1996. 5 In order to verify these recommendations, in vitro interference studies were then performed in three European laboratories. The results of these studies and the recommendations of the expert group are the subject of this paper.
METHOD Part I: List of drugs recommended for interference studied
Each expert provided a list of candidate drugs for interference testing. From a list of 101 drugs the experts identi®ed 18 in serum (see Table 1 ) and 13 in urine (see Table 2 ) which were likely to present frequent, clinically signi®cant interference. This exercise drew support from Swedish 6, 7 French, 8, 9 English 10 and American 11 databases, and from other published reports. 12±18 From a review of the literature, the group identi®ed toxic and therapeutic concentrations for each of the 24 drugs. 6,17,19±32 Inclusion criteria used to select drugs for the in vitro study were:
Drug interference in clinical chemistry 377 For the urine studies, if metabolites are excreted in place of the parent drug the major metabolite should be used; however, this is subject to the availability of the metabolite.
Two different concentrations of each drug were adopted. To reveal potential interference in in vitro screening a very high drug concentration (C1) was used. C1 represents a typical toxic concentration, and where interference was identi®ed a validation experiment was performed using a therapeutic drug concentration (C2).
Two tables were prepared, one for blood (see Table 1 ) and the other for urine (see Table 2 ). These include the international non-proprietary name (INN) of the drug, its clinical use, drug concentrations C1 and C2, and the highest blood and urine drug found in the literature. Therapeutic peak and toxic concentrations have been included where they are available.
When studying drug interference the analyte concentration used should be close to a clinical decision level, perhaps the upper or lower normal reference limit. This recommendation was adopted in the validation experiment.
Part II: Veri®cation experiment Procedure
The study covered two phases: a screen for effects at elevated drug levels (C1) and a validation phase to check for interference at more clinically relevant levels (C2).
Screening (C1)
In the screening experiment ®ve replicates of a drug-free pool were analysed, followed by analysis of ®ve replicates of a pool containing the drug under investigation. A simple automatic wash step as typically programmed in the instrument was performed between each sample to minimize sample carry-over.
Validation (C2)
In the validation experiment, analysis of 10 replicates of the drug-free pool was followed by analysis of 10 replicates of the spiked drug pool, with a wash step between each sample.
Material
The methods used in these studies (see Tables 3  and 4 ) were all performed on Hitachi 917 analysers (Roche Diagnostics, Mannheim, Germany). In both experiments the analytical system was calibrated and quality controlled according to the recommendations of the manufacturer. For each analyte a drug-free pool of serum or urine was collected by the three laboratories (Kantonsspital, Basel, Switzerland; Hospital Germans Trias i Pujol, Barcelona, . The drug-free pools were prepared from donors taking no drugs. Spiked drug pools were prepared from either the parent drug or its metabolite. Ethanol was used as a solvent for those drugs that were insoluble in water. The pools prepared for studying therapeutic drugs or drugs of abuse were spiked with the parent drug (Sigma, Buchs, Switzerland). These drugs were:
Drugs of abuse D,L-amphetamine sulphate, Na-barbiturate, Dlysergic acid diethylamide, propoxyphene-HCl and phencyclidine-HCl.
Therapeutic drugs
Digitoxin (Fluka, Buchs, Switzerland), digoxin, gentamicin, phenobarbital, phenytoin, theophyllin, tobramycine, valproic acid.
Statistics
Data were subject to statistical analysis using Computer-Aided Evaluation software (Roche, Mannheim, Germany) developed by Bablok et al. 33 Interpretation A clinically acceptable degree of interference, termed interference limit, was agreed by the expert group for each analyte studied and is included in Tables 3 and 4 . These limits were derived from inspection of analytical performance data in German, English and French external quality assessment schemes (EQAS). The clinical signi®cance of these analytical limits was reviewed and modi®ed by the group to provide the recommendations included in Tables  3 and 4 . Drugs that showed interference in the screening experiment were included in the validation study, and only those that then demonstrated interference were considered to be clinically relevant.
RESULTS
The results of the validation experiment at clinically relevant drug concentrations are given in Tables 3 and 4 . The results of the screening experiment using high drug concentrations (C1) have not been included but are available on request to the corresponding author.
The following analytes in serum showed no interference at high (C1) and normal (C2) drug concentrations when using the methods described in Table 3 : alkaline phosphatase, amylase, aspartate aminotransferase, cholinesterase, b-hydroxy butyrate dehydrogenase, lactate dehydrogenase, albumin, glucose, total protein, gentamicin, thyroxine (T 4 ), a 1 -acid glycoprotein, a 1 -microglobulin, b 2 -microglobulin, apolipoprotein A1, apolipoprotein B, antistreptolysin-O, C-reactive protein, ferritin, IgA, IgG, IgM, prealbumin, transferrin; and in Table 4 in urine for amphetamines, cannabinoids, methadone, opiates and propoxyphene.
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Ann Clin Biochem 2001: 38 Drug interference was observed in serum at normal (C2) drug concentrations for acid phosphatase, creatine kinase MB, total bilirubin, creatinine, fructosamine, triglycerides, uric acid, carbamazepine, digitoxin, phenytoin, theophylline, tobramycin, valproic acid, complement 3 (C3), complement 4 (C4) and rheumatoid factor (see Table 3 ).
Interference was also observed in urine at normal (C2) drug concentrations for amylase, magnesium, b 2 -microglobulin and total protein (see Table 4 ).
DISCUSSION AND CONCLUSION
Most analytes showed no drug interference even at the very high drug concentrations that might be seen with suicidal overdoses. This should reassure both clinical laboratories and manufacturers of clinical chemistry analysers.
Drug interference studies can be misleading in some clinical situations and this is illustrated below:
.
Levodopa is metabolized into the endogenous substances dihydroxyphenylacetic acid and homovanillic acid. Clearly, this makes the use of metabolite in drug interference studies dif®cult. Interference can therefore be mediated either by a pathological process producing these metabolites or by drug interference. .
The metabolites of ibuprofen, (+)-2-[p-(2 hydroxymethyl-propyl) phenyl] propionic acid and (+)-2-[p-(2 carboxy-propyl) phenyl] propionic acid were not available for this study. The use of the parent drug in place of the metabolites cannot adequately re¯ect physiological conditions and might therefore be misleading.
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Ann Clin Biochem 2001: 38 The interfering potential of the drugs marked as`known' in Tables 3 and 4 has already been recognized and published. 1±9,11 This study identi®ed the following new interferants: acid phosphatase in serum by ibuprofen and theophylline; non-prostatic acid phosphatase in serum by cefoxitin and doxycycline; creatine kinase MB in serum by doxycycline; total bilirubin in serum (Jendrassik± Grof method) by rifampicin and intralipid; total bilirubin in serum (DPD method) by intralipid; creatinine in serum (Jaffe method) by cefoxitin; fructosamine in serum by levodopa and methyldopa; uric acid in serum by levodopa, methyldopa and tetracycline; carbamazepine in serum by doxycycline, levodopa, methyldopa and metronidazole; digitoxin in serum by rifampcin; phenytoin in serum by doxycycline, ibuprofen, metronidazole and theophylline; theophylline in serum by acetaminophen, cefoxitin, doxycycline, levodopa, phenylbutazone and rifampicin; tobramycin in serum by cefoxitin, doxycycline, levodopa, rifampicin and phenylbutazone; valproic acid in serum by phenylbutazone; C3 in serum by intralipid; C4 in serum by doxycycline; rheumatoid factor in serum by ibuprofen and metronidazole; pancreatic amylase and total amylase in urine by acetylcysteine, ascorbic acid, cefoxitin, gentamicin, levodopa, methyldopa and o¯oxacin; magnesium in urine by acetylcysteine, gentamicin and methyldopa; b 2 -microglobulin in urine by ascorbic acid; total protein in urine by ascorbic acid, Ca-dobesilate and phenylbutazone.
Interference in acid phosphatase, creatine kinase MB and bilirubin methods was observed at very low analyte concentrations, and therefore it may not be evident at higher concentrations.
In vitro studies cannot accurately re¯ect the in vivo interference effects of drugs and their metabolites. This study has identi®ed those drugs that cause interference under in vitro conditions, but cannot be considered either de®nitive or comprehensive. Rapid developments in analytical chemistry and the introduction of new and more complex drug preparations makes it essential that the clinical chemist remains vigilant to the potential for drug interference. The goal of this study was to present a model for further interference studies for manufacturer of diagnostic kits or clinical chemists evaluating a new method. The mechanism of interference was not investigated in this study and should be further investigated.
